New pill aims to halt blinding eye disease in major trial

NCT ID NCT05949593

Ongoing Disease control Sponsor: Belite Bio, Inc Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a daily oral medication called Tinlarebant can slow the progression of geographic atrophy (GA), an advanced form of age-related macular degeneration that causes permanent vision loss. About 429 participants with GA will be randomly assigned to take either the study drug or a placebo pill daily for two years. The main goal is to see if the drug reduces the rate at which the damaging eye lesions grow, which could help preserve vision.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Belite Study Site

Phoenix, Arizona, 85020, United States
Belite Study Site

Arcadia, California, 91007, United States
Belite Study Site

Beverly Hills, California, 90211, United States
Belite Study Site

Huntington Beach, California, 92467, United States
Belite Study Site

Los Angeles, California, 90033, United States
Belite Study Site

Palo Alto, California, 94303, United States
Belite Study Site

San Diego, California, 92093, United States
Belite Study Site

Lakeland, Florida, 33805, United States
Belite Study Site

Hagerstown, Maryland, 21740, United States
Belite Study Site

Saint Louis Park, Minnesota, 55416, United States
Belite Study Site

Westbury, New York, 11590, United States
Belite Study Site

Cary, North Carolina, 27511, United States
Belite Study Site

Durham, North Carolina, 27710, United States
Belite Study Site

Wake Forest, North Carolina, 27587, United States
Belite Study Site

Portland, Oregon, 97239, United States
Belite Study Site

Philadelphia, Pennsylvania, 19107, United States
Belite Study Site

Sewickley, Pennsylvania, 15143, United States
Belite Study Site

Germantown, Tennessee, 38138, United States
Belite Study Site

Abilene, Texas, 79606, United States
Belite Study Site

Dallas, Texas, 75231, United States
Belite Study Site

San Antonio, Texas, 78240, United States
Belite Study Site

Warrenton, Virginia, 20186, United States
Belite Study Site

Chatswood, New South Wales, 2067, Australia
Belite Study Site

Strathfield, New South Wales, 2135, Australia
Belite Study Site

Brisbane, Queensland, 4101, Australia
Belite Study Site

Adelaide, South Australia, 5000, Australia
Belite Study Site

East Melbourne, Victoria, 3002, Australia
Belite Study Site

Crawley, Western Australia, 6009, Australia
Belite Study Site

Beijing, Beijing Municipality, 100044, China
Belite Study Site

Chengdu, Sichuan, 610093, China
Belite Study Site

Beijing, 10005, China
Belite Study Site

Beijing, 100730, China
Belite Study Site

Guandong, 510060, China
Belite Study Site

Zhejiang, 325027, China
Belite Study Site

Ostrava, 70852, Czechia
Belite Study Site

Prague, 14000, Czechia
Belite Study Site

Prague, 14059, Czechia
Belite Study Site

Dijon, 21000, France
Belite Study Site

Écully, 69130, France
Belite Study Site

Lyon, 69317, France
Belite Study Site

Marseille, 130008, France
Belite Study Site

Basel, 4031, Switzerland
Belite Study Site

Lausanne, 1001, Switzerland
Belite Study Site

Taichung, 40447, Taiwan
Belite Study Site

Taipei, 100, Taiwan
Belite Study Site

Taoyuan District, 33305, Taiwan
Belite Study Site

Great Yarmouth, NR31 6LA, United Kingdom
Belite Study Site

Harrow, HA1 3UJ, United Kingdom
Belite Study Site

London, EC1V 2PD, United Kingdom

Conditions

Explore the condition pages connected to this study.

GEOGRAPHIC ATROPHY